Zhejiang Ausun Pharmaceutical Co Ltd Net Asset Quality Index
Zhejiang Ausun Pharmaceutical Co Ltd net asset quality index. Zhejiang Ausun Pharmaceutical Co Ltd (603229) has a Net Asset Quality Index of 75.0% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥3.16 Billion minus total liabilities of CN¥789.65 Million yields net assets of CN¥2.37 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See 603229 net asset value for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Zhejiang Ausun Pharmaceutical Co Ltd (2012–2025)
Net asset quality index of Zhejiang Ausun Pharmaceutical Co Ltd from 2012 to 2025. This chart shows how Zhejiang Ausun Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 14 annual periods from 2012 to 2025. As of March 2026, the index stands at 75.0%, representing net assets of CN¥2.37 Billion against total assets of CN¥3.16 Billion CNY. Check Zhejiang Ausun Pharmaceutical Co Ltd (603229) strategic asset index to assess the company's strategic physical and investment asset allocation.
Zhejiang Ausun Pharmaceutical Co Ltd Net Asset Quality Index by Year (2012–2025)
Zhejiang Ausun Pharmaceutical Co Ltd net asset quality index by year from 2012 to 2025. The table below presents the year-by-year Net Asset Quality Index for Zhejiang Ausun Pharmaceutical Co Ltd from 2012 to 2025, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 603229 market cap.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 73.6% | CN¥2.27 Billion | CN¥3.09 Billion | CN¥815.89 Million | ▼ -2.6 pp |
| 2024 | 76.2% | CN¥2.27 Billion | CN¥2.98 Billion | CN¥710.50 Million | ▲ +3.6 pp |
| 2023 | 72.6% | CN¥2.14 Billion | CN¥2.95 Billion | CN¥809.99 Million | ▲ +9.4 pp |
| 2022 | 63.1% | CN¥1.46 Billion | CN¥2.32 Billion | CN¥854.19 Million | ▼ -5.1 pp |
| 2021 | 68.2% | CN¥1.25 Billion | CN¥1.84 Billion | CN¥584.64 Million | ▼ -13.3 pp |
| 2020 | 81.6% | CN¥1.13 Billion | CN¥1.38 Billion | CN¥254.81 Million | ▲ +8.8 pp |
| 2019 | 72.8% | CN¥645.19 Million | CN¥886.14 Million | CN¥240.96 Million | ▼ -1.7 pp |
| 2018 | 74.5% | CN¥597.60 Million | CN¥801.98 Million | CN¥204.38 Million | ▼ -1.7 pp |
| 2017 | 76.2% | CN¥564.93 Million | CN¥741.58 Million | CN¥176.65 Million | ▲ +21.6 pp |
| 2016 | 54.5% | CN¥243.30 Million | CN¥446.06 Million | CN¥202.76 Million | ▲ +7.7 pp |
| 2015 | 46.8% | CN¥188.07 Million | CN¥401.89 Million | CN¥213.81 Million | ▲ +16.7 pp |
| 2014 | 30.1% | CN¥78.21 Million | CN¥260.11 Million | CN¥181.90 Million | ▲ +11.7 pp |
| 2013 | 18.4% | CN¥32.91 Million | CN¥178.78 Million | CN¥145.87 Million | ▲ +10.0 pp |
| 2012 | 8.4% | CN¥10.36 Million | CN¥122.57 Million | CN¥112.21 Million | — |